Nordic Life Science 1
Hans Schambye, CEO, Galecto F IN A NC IN G THE CO
MPLETED EQUITY FINANCING WILL BE USED TO ACCELERATE THE DEVELOPMENT OF THE COMPANY’S CLINICAL PIPELINE. G ALECTO INTENDS TO use the funds to prepare for a potential conditional approval of GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in the European Union and to further expand and advance its clinical development pipeline. The company is conducting a Phase 2b trial of GB0139 in IPF and intends to initiate Phase 2 studies of GB1211 in liver fibrosis related to non-alcoholic steatohepatitis and GB2064 in myelofibrosis by the end of this year. The financing was led by Soleus Capital and co-led by Eir Ventures.